Theravance Biopharma (TBPH) Interest Expenses (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Interest Expenses data on file, last reported at $64000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses fell 90.05% year-over-year to $64000.0 in Q1 2026; TTM through Mar 2026 was $64000.0, a 97.5% decrease from a year earlier, with the FY2025 full-year figure at $436.3 million, changed 0.18% from the prior year.
• Interest Expenses for Q1 2026 stood at $64000.0, down from $9.4 million in the prior quarter.
• Over the last five years, Interest Expenses for TBPH reached as high as $9.4 million in Q4 2025 and fell as low as $64000.0 in Q1 2026.
• Historically, Interest Expenses has averaged $1.9 million across 5 years, with a median of $643000.0 in 2024.
• Across the five-year window, Interest Expenses sank 92.2% in 2024 and surged 1356.61% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $1.5 million in 2022, then jumped by 433.27% to $8.2 million in 2023, then sank by 92.2% to $643000.0 in 2024, then jumped by 1356.61% to $9.4 million in 2025, then slumped by 99.32% to $64000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $64000.0 in Q1 2026, $9.4 million in Q4 2025, and $573000.0 in Q3 2025.